<DOC>
	<DOCNO>NCT00023231</DOCNO>
	<brief_summary>The purpose study see effect use drug calcineurin inhibitor improve rate kidney transplant failure . Kidney transplantation help child end-stage kidney disease . However , difficult find treatment donor graft rejection lot side effect . Researchers hope find treatment ( immunosuppressant ) few side effect . One approach avoid use calcineurin inhibitor try new drug know sirolimus instead . Another use steroids less often . This study test whether use sirolimus , few steroid treatment , MMF , certain antibody improve long-term graft survival child receive kidney transplant live donor .</brief_summary>
	<brief_title>Pediatric Kidney Transplant Without Calcineurin Inhibitors</brief_title>
	<detailed_description>Renal transplantation widely recognize treatment choice child end-stage renal disease ( ESRD ) . Although outcomes renal transplantation child improve past decade , success limit non-specific tolerance complication associate immunosuppressant . Steroids calcineurin inhibitor toxic side effect . Use sirolimus immunosuppression associate many complication . Recent study Europe demonstrate sirolimus combine MMF steroid provide excellent graft survival absence calcineurin inhibitor . Steroid side-effects lessen taper steroid dose every-other-day schedule . This protocol test whether immunosuppression IL-2r antibody , sirolimus , MMF , alternate-day steroid provide comparable graft survival live donor recipient , compare current immunosuppression , reduce complication calcineurin inhibitor . Evaluations prior transplantation include complete history physical examination , CBC , liver function test , antibody CMV , EBV , HIV , HbsAG , HCV . All appropriate vaccination provide transplantation . Transplant recipient receive immunosuppression therapy use antibody induction ( daclizumab ) , corticosteroid , mycophenolate mofetil , sirolimus . Serum sirolimus level measure dos adjust maintain certain blood level drug . Bactrim ganciclovir give infection prophylaxis . If patient consistent high level fast cholesterol , treatment lipitor may give . A transplant biopsy perform time transplant 3 , 6 , 12 month post transplantation time rejection suspect . A radionuclide GFR do time point , 1 , 24 , 36 month . The protocol biopsy , blood , urine sample analyze genomic method determine difference gene expression post transplantation . In event first acute rejection , patient treat Solu-Medrol 3 consecutive day . A second rejection ( discretion transplant center ) severe rejection ( Banff Grade 3 ) treat antibody therapy , second severe rejection , immunosuppressant regimen change . Patients follow 36 month routine physical examination laboratory assessment .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are 21 year age . Are kidney recipient livingdonor graft , except livingdonor graft identically match . Exclusion Criteria Patients eligible study : Are recipients identical ( HLA match ) livingdonor graft . Are recipient cadaverdonor graft . Have certain abnormal kidney disease may return . Have fail 2 previous kidney transplant . Have fat abnormality inherit present high level .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>